{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:05Z","timestamp":1787008625020,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005423","name":"Uppsala University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amphotericin B-based treatment has been the cornerstone of Candida infective endocarditis (CIE) treatment, but recent guidelines also recommend echinocandins. However, there are limited outcome data. The few studies performed report differing results. Our aim in this study was to compare the outcome with echinocandins to those of other antifungal strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A CIE cohort was derived from the Swedish Registry of Infective Endocarditis for 1995\u20132019. In-hospital mortality or relapse was considered treatment failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>51 episodes in 38 patients were treated with echinocandins (n = 21), amphotericin B-based therapy (n = 22), or azoles (n = 8). The proportions of treatment failure were 32%, 38%, and 62%, respectively (P = .35). Patients who received echinocandins were older and had a higher burden of comorbidities. The overall 1-year mortality rate from index hospitalization was 26%, with no significant differences between backbone therapies (P = .18). Because Candida parapsilosis IE was not treated with echinocandins, a subgroup analysis was performed of 33 episodes with C. non-parapsilosis that showed no significant differences between backbone therapies (P = .33). In a subgroup analysis of episodes treated with amphotericin B-based therapy, treatment failure was seen in 54% of 13 episodes caused by C. parapsilosis and 12% of 8 episodes caused by C. non-parapsilosis (P = .10).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No differences in in-hospital mortality, relapse rate, or 1-year mortality were seen in patients with echinocandin-based therapy compared with other CIE regimens, despite risk factors in the echinocandin group that would be expected to negatively bias outcome. Candida parapsilosis CIE appears to pose specific challenges in terms of optimal therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf312","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T07:46:54Z","timestamp":1749800814000},"page":"e455-e461","source":"Crossref","is-referenced-by-count":5,"title":["Antifungal Therapy in\n                    <i>Candida<\/i>\n                    Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0034-0609","authenticated-orcid":false,"given":"Siri","family":"Kurland","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Infection Medicine, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Furebring","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infection Medicine, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"L\u00f6wdin","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infection Medicine, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Olaison","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sj\u00f6lin","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infection Medicine, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"2026031619513539100_ciaf312-B1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10096-008-0466-x","article-title":"Candida infective endocarditis","volume":"27","author":"Baddley","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026031619513539100_ciaf312-B2","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.1111\/j.1469-0691.2012.03764.x","article-title":"Diagnosis, management and outcome of Candida endocarditis","volume":"18","author":"Lefort","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026031619513539100_ciaf312-B3","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.04867-14","article-title":"Candida infective endocarditis: an observational cohort study with a focus on therapy","volume":"59","author":"Arnold","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619513539100_ciaf312-B4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijid.2018.09.016","article-title":"Outcomes in patients with fungal endocarditis: a multicenter observational cohort study","volume":"77","author":"Siciliano","year":"2018","journal-title":"Int J Infect Dis"},{"key":"2026031619513539100_ciaf312-B5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/cid\/cix913","article-title":"Prosthetic valve Candida spp. endocarditis: new insights into long-term prognosis\u2014the ESCAPE study","volume":"66","author":"Rivoisy","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026031619513539100_ciaf312-B6","doi-asserted-by":"crossref","first-page":"101215","DOI":"10.1016\/j.mam.2023.101215","article-title":"The changing epidemiology of fungal infections","volume":"94","author":"Lass-Fl\u00f6rl","year":"2023","journal-title":"Mol Aspects Med"},{"key":"2026031619513539100_ciaf312-B7","doi-asserted-by":"crossref","first-page":"643335","DOI":"10.3389\/fcell.2021.643335","article-title":"Anti-biofilm approach in infective endocarditis exposes new treatment strategies for improved outcome","volume":"9","author":"Lerche","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026031619513539100_ciaf312-B8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.semtcvs.2015.12.005","article-title":"Current hypotheses in cardiac surgery: biofilm in infective endocarditis","volume":"28","author":"Elgharably","year":"2016","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"2026031619513539100_ciaf312-B9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/IAI.70.2.878-888.2002","article-title":"Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces","volume":"70","author":"Kuhn","year":"2002","journal-title":"Infect Immun"},{"key":"2026031619513539100_ciaf312-B10","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1128\/AAC.46.11.3634-3636.2002","article-title":"In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies","volume":"46","author":"Ramage","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619513539100_ciaf312-B11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2026031619513539100_ciaf312-B12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026031619513539100_ciaf312-B13","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC guidelines for the management of endocarditis","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur Heart J"},{"issue":"Suppl 7","key":"2026031619513539100_ciaf312-B14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026031619513539100_ciaf312-B15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/14787210.2017.1372749","article-title":"Candida endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis","volume":"15","author":"Giuliano","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026031619513539100_ciaf312-B16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/313753","article-title":"Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis","volume":"30","author":"Li","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2026031619513539100_ciaf312-B17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.7326\/0003-4819-150-9-200905050-00004","article-title":"Health care-associated native valve endocarditis: importance of non-nosocomial acquisition","volume":"150","author":"Benito","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026031619513539100_ciaf312-B18","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2026031619513539100_ciaf312-B19","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/AAC.46.6.1773-1780.2002","article-title":"Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins","volume":"46","author":"Kuhn","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619513539100_ciaf312-B20","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1128\/AAC.00316-09","article-title":"Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates","volume":"53","author":"Ferreira","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619513539100_ciaf312-B21","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"2026031619513539100_ciaf312-B22","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"2026031619513539100_ciaf312-B23","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026031619513539100_ciaf312-B24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"2026031619513539100_ciaf312-B25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/AAC.39.1.40","article-title":"Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group","volume":"39","author":"Rex","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619513539100_ciaf312-B26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1128\/AAC.05872-11","article-title":"Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata","volume":"56","author":"Spreghini","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619513539100_ciaf312-B27","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/cid\/ciy684","article-title":"Impact of valve culture in the prognosis of active left-sided infective endocarditis","volume":"68","author":"Garc\u00eda-Granja","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026031619513539100_ciaf312-B28","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s40121-022-00642-8","article-title":"Impact of valve culture positivity on prognosis in patients with infective endocarditis who underwent valve surgery","volume":"11","author":"Kim","year":"2022","journal-title":"Infect Dis Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf312\/63490932\/ciaf312.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/3\/e455\/63490932\/ciaf312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/3\/e455\/63490932\/ciaf312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:51:49Z","timestamp":1773705109000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/3\/e455\/8162706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6,14]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf312","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,15]]},"published":{"date-parts":[[2025,6,14]]}}}